The research, led by Xinxin Zhang of Jiading District Central Hospital and Jianguang Jia of Bengbu Medical University, drew on publicly available data from The Cancer Genome Atlas Stomach Adenocarcinoma collection (TCGA-STAD) and The Cancer Imaging Archive (TCIA). From these resources, the team assembled a matched cohort of 46 gastric cancer patients for whom CT imaging, transcriptomic profiles, and clinical records were all available. While modest in size, the cohort allowed the investigators to build and test an integrated model that links what a tumor looks like on a scanner with what its genes are doing at the molecular level.

The imaging side of the pipeline relied on radiomics, a technique that converts medical images into hundreds of quantitative descriptors. Using the open-source PyRadiomics toolkit, the researchers extracted 116 features from CT regions of interest. These included texture measures derived from gray-level co-occurrence, run-length, size-zone, dependence, and neighborhood gray-tone difference matrices, all of which capture subtle patterns of heterogeneity within the tumor that the human eye cannot reliably perceive. To avoid overfitting, the team applied least absolute shrinkage and selection operator (LASSO) based L1-regularized logistic regression, a method that shrinks irrelevant coefficients to zero, and retained eleven of the most informative radiomic features for downstream modeling.

On the genomics side, the researchers took a network-based approach rather than analyzing thousands of individual genes. After normalizing transcriptomic data with Z-score transformation, they applied Weighted Gene Co-expression Network Analysis, or WGCNA, a widely used method that clusters genes with correlated expression patterns into modules. The analysis identified seven such transcriptomic modules, each summarized by a single value known as a module eigengene, which is essentially the first principal component of the module’s expression profile. Condensing thousands of genes into seven eigengenes provided a low-dimensional, biologically meaningful representation of tumor transcriptional behavior, sidestepping the curse of dimensionality that plagues genomic prediction models.

These radiomic features, module eigengenes, and clinical variables were then fed into a random forest classifier, an ensemble algorithm that builds many decision trees on bootstrapped samples of the data and averages their votes. Random forests are prized in biomedical machine learning for their robustness to noise, their tolerance of mixed data types, and their resistance to overfitting on small datasets, properties well suited to a cohort of this scale. The cohort was split into a training and internal-validation set of 37 patients and a held-out evaluation set of 9 patients, with stratified five-fold cross-validation performed within the training set to estimate performance more reliably.

The results were encouraging for an exploratory study of this size. In cross-validation, the random forest model achieved an area under the receiver operating characteristic curve of 0.85, with a 95 percent confidence interval ranging from 0.68 to 0.97. On the held-out evaluation set, the model reached an accuracy of 0.78, with precision and recall for the survival class each at 0.80, and a weighted F1 score of 0.78. An AUC of 0.85 suggests the model distinguishes survivors from non-survivors considerably better than chance, while the consistency between cross-validation and held-out performance hints that the multimodal signal is not merely an artifact of the training data.

The appeal of the approach lies in its multimodality. CT radiomics capture the physical phenotype of the tumor, including its texture, shape, and internal heterogeneity, which are influenced by factors such as cell density, necrosis, and angiogenesis. Transcriptomic module eigengenes reflect the underlying molecular machinery, from immune infiltration to proliferative signaling. Clinical variables anchor both in the patient’s real-world context. By integrating all three, the model can, in principle, detect survival-relevant signals that no single data type contains on its own, a principle increasingly recognized across precision oncology.

The authors are careful to frame the work as exploratory. With only 46 patients, the confidence intervals are wide, and the held-out set of nine patients is far too small to serve as definitive external validation. The study is also retrospective, relying on publicly available de-identified data rather than a prospectively enrolled cohort, and the researchers note that no additional ethical approval was required for this secondary analysis. Larger, independent, and ideally multi-center cohorts will be needed to determine whether the model generalizes beyond this dataset, whether the same radiomic and transcriptomic features remain predictive across scanners and populations, and whether the approach outperforms existing clinicopathological risk stratification.

Still, the study adds to a rapidly growing body of literature showing that routine clinical imaging, ordinarily used for diagnosis and staging, contains a wealth of quantitative prognostic information waiting to be unlocked. Because CT scans are already obtained as part of standard gastric cancer workups, a validated radiomics-based model could eventually be deployed at little additional cost to the patient, potentially flagging high-risk individuals who might benefit from more aggressive treatment or closer surveillance. Coupling such models with genomic modules could further point clinicians toward the biological drivers behind a poor imaging phenotype.

The work was supported in part by the 2024 National Clinical Key Specialty Construction Project and several Shanghai Jiading District research funds. As artificial intelligence continues to seep into radiology and oncology, studies like this one illustrate both the promise and the discipline required: sophisticated multimodal models can extract striking predictive signals from small cohorts, but translating them into clinical tools will demand the kind of rigorous, large-scale validation that only broader collaborations can provide.

Gastric cancer, noted for its high mortality rates worldwide, is typified by an insidious ability to both proliferate aggressively and subvert immune defenses. Central to this evasion is the tumor microenvironment, a complex network of cellular crosstalk and signaling pathways. Despite extensive investigation, the exact molecular mechanisms that promote tumor-associated macrophage (TAM) polarization towards a pro-tumor, immunosuppressive phenotype, and the subsequent functional exhaustion of cytotoxic CD8+ T cells, have remained elusive.

Leveraging the expansive data repository of The Cancer Genome Atlas (TCGA), the researchers initially identified that SULF1 expression is markedly elevated in gastric cancer tissues compared to normal gastric epithelium. Notably, this upregulation correlates strongly with advanced tumor stages and poor overall patient survival, suggesting that SULF1 could serve as both a prognostic biomarker and an active contributor to disease progression rather than a mere bystander.

To translate these bioinformatic findings into functional insights, Lu and Lu employed CRISPR/Cas9 gene editing alongside lentiviral-mediated gene overexpression to modulate SULF1 levels in gastric cancer cell lines. Cells with suppressed SULF1 expression displayed significantly reduced proliferation, migration, and invasion capacities, coupled with enhanced apoptotic rates. In stark contrast, augmenting SULF1 levels amplified malignant behaviors, underscoring the protein’s direct pro-tumorigenic influence.

Beyond tumor cell intrinsic effects, the investigation delved into SULF1’s role in orchestrating immune cell dynamics within the tumor niche. Co-culture experiments involving human macrophages exposed to conditioned media from SULF1-overexpressing gastric cancer cells revealed induction of the M2 macrophage polarization phenotype, characterized by immune suppression and tissue remodeling functions that typically facilitate tumor progression.

In parallel, CD8+ T cells subjected to the same experimental conditions exhibited hallmark features of exhaustion—a dysfunctional state manifesting as reduced cytokine production, diminished cytotoxic granule release, and impaired proliferative capacity. Flow cytometric analyses quantitatively confirmed that elevated SULF1 prompts a shift in T cell functionality towards this exhausted phenotype, a major barrier to effective anti-tumor immunity.

Sifting through intracellular signaling pathways, the study highlighted the STAT3 pathway as a critical mediator of SULF1’s immunomodulatory activities. Biochemical assays, including immunoblotting and nuclear translocation evaluations, revealed that SULF1 activates STAT3 signaling within macrophages. This activation drives M2 polarization and subsequently fosters an immunosuppressive milieu capable of blunting cytotoxic T cell responses.

A particularly striking component of the research involved in vivo validation using murine models of gastric cancer. Silencing SULF1 in tumor cells implanted into mice led to pronounced tumor regression accompanied by reduced markers of T cell exhaustion within the tumor microenvironment. Conversely, exogenous supplementation of secreted SULF1 protein reinstated the immunosuppressive conditions and accelerated tumor growth, cementing the causal role of SULF1 in shaping tumor immunity.

The implications of these findings are profound. They position SULF1 not only as an oncogenic factor intrinsic to gastric cancer cells but as a potent architect of the tumor microenvironment’s immune landscape, pivoting the balance towards immune escape and tumor sustenance. This dual action opens exciting therapeutic possibilities to disrupt this deleterious axis.

Currently, immunotherapies targeting exhausted T cells, such as immune checkpoint inhibitors, are limited by the complex suppressive networks imposed by TAMs and other stromal components. By targeting the SULF1-STAT3 signaling circuit, it may be possible to reprogram macrophages away from their M2 state and restore CD8+ T cell activity, thereby sensitizing tumors to existing and emerging immunotherapeutic regimens.

Additionally, the study’s integration of multi-dimensional experimental approaches—from genome-wide data mining to precise gene editing, immune cell functional assays, and in vivo modeling—exemplifies an innovative paradigm for unraveling the tumor-immune interface. The comprehensive elucidation of SULF1’s role offers an archetype for similar molecular dissection in other cancer types exhibiting immune evasion.

Beyond gastric cancer, the secreted nature of SULF1 suggests it might also modulate systemic immune responses, potentially influencing metastatic niches or distant immune organs. Future investigations exploring SULF1 expression patterns across cancers and its systemic immunological impact could broaden its relevance as a clinical target.

In summary, Lu and Lu’s research delivers compelling evidence that secreted SULF1 protein is a key orchestrator of tumor immune evasion in gastric cancer, primarily through activation of STAT3-dependent macrophage polarization and consequent CD8+ T cell exhaustion. Their work not only refines our molecular understanding of tumor-host immune dynamics but also ushers in novel strategies for enhancing anti-tumor immunity by disrupting this newly characterized axis.

As gastric cancer continues to pose significant clinical challenges with limited therapeutic responsiveness, targeting the SULF1-STAT3 pathway emerges as an alluring, innovative strategy. This discovery spotlights a critical mechanistic node ripe for drug development, with the potential to improve patient outcomes by reinvigorating immune-mediated tumor control and curtailing cancer progression.

The confluence of molecular biology, immunology, and clinical oncology in this work underscores the transformative power of interdisciplinary approaches in cancer research. Looking forward, incorporation of SULF1-targeted therapies with existing treatment modalities may herald a new era of precision immuno-oncology in gastric cancer and beyond, catalyzing durable remissions and enhanced survival for affected patients.

Subject of Research: Gastric cancer immunology, tumor microenvironment, SULF1 regulation, macrophage polarization, CD8+ T cell exhaustion, STAT3 signaling

Article Title: Secreted SULF1 protein modulates CD8+ T cell exhaustion by promoting TAM polarization in gastric cancer

Article References:
Lu, X., Lu, D. Secreted SULF1 protein modulates CD8 + T cell exhaustion by promoting TAM polarization in gastric cancer. Genes Immun (2026). https://doi.org/10.1038/s41435-026-00399-x

Image Credits: AI Generated

DOI: 10.1038/s41435-026-00399-x (15 April 2026)